ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: tocilizumab

ACR Releases New Guideline for Management of SLE at ACR 2025

Mithu Maheswaranathan, MD  |  

Updating the last iteration in 1999, the new ACR Guideline for Management of SLE was unveiled at ACR Convergence 2025, providing rheumatologists an organ-based approach for therapeutic options for specific lupus manifestations.

JIA: The Transition to Adult Care

  |  

Experts addressed considerations for how to aid patients with juvenile idiopathic arthritis (JIA) in their transition to adult care, specifically highlighting clinical pearls for those with pediatric uveitis and TMJ arthritis.

Calcium Pyrophosphate Deposition Disease Diagnosis & Treatment Gaps Remain

  |  

CPPD diagnosis is difficult & treatments are limited. Experts review radiology challenges, off-label options like colchicine, & emerging biologics.

Let’s Discuss Part 2: More Insights from the ACR Convergence 2025 Review Course

  |  

The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on cutaneous manifestations of rheumatic diseases, gout, macrophage activation syndrome and vasculitis.

Let’s Discuss: Insights from the ACR Convergence 2025 Review Course

  |  

The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on SLE and lupus nephritis, inflammatory brain diseases, drug management of rheumatic diseases and mimics of inflammatory myopathies.

Cardiovascular Risks Similar for JAK Inhibitors & bDMARDs

  |  

Using data from registries across Europe and Canada, Aymon et al. compared the incidence of major adverse cardiac events (MACE) in patients with RA treated with JAK inhibitors, TNF inhibitors or biologic DMARDs with other modes of action over two years. The researchers did not find an increased risk of MACE with JAK inhibitors over that time frame.

Guidelines for ILD in Systemic Autoimmune Rheumatic Disease

  |  

Over 50% of patients with systemic sclerosis (SSc) develop interstitial lung disease (ILD), and rheumatologists have long recognized this major cause of morbidity and mortality.1 Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, and director of the Toronto Sclero­derma Program, notes that more recent studies have increased our awareness…